CIAM
LRMR icon

Caitong International Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Caitong International Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9K Sell
3,886
-27,461
-88% -$109K ﹤0.01% 1122
2026
Q1 		$141K Buy
31,347
+30,159
+2,539% +$121K 0.03% 477
2025
Q4 		$4.53K Buy
+1,188
New +$4.62K ﹤0.01% 1244

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Caitong International Asset Management's LRMR Position: Q2 2026 in Review

Caitong International Asset Management reduced its Larimar Therapeutics (LRMR) stake by 88% in Q2 2026, selling an estimated $109K and leaving 3,886 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Caitong International Asset Management first reported a position in LRMR in Q4 2025 and has held it in 3 quarters since. The position peaked at $141K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Caitong International Asset Management held 3,886 shares of Larimar Therapeutics worth $11.9K as of Q2 2026.
  • Caitong International Asset Management sold 27,461 Larimar Therapeutics shares in Q2 2026, an estimated $109K.
  • Larimar Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1122 holding.
  • Caitong International Asset Management first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Caitong International Asset Management's Larimar Therapeutics position peaked at $141K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.